comparemela.com

Latest Breaking News On - Sanjays shukla - Page 6 : comparemela.com

aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of efzofitimod as Nonproprietary Name Seite 1

13.01.2022 - Efzofitimod expected to enter into a registrational trial for pulmonary sarcoidosis in 2022SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) - aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of . Seite 1

Novel Immunomodulator Gets Orphan Drug Status for Sarcoidosis

The Food and Drug Administration has granted Orphan Drug designation to ATYR1923 for the treatment of sarcoidosis.

aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

aTyr Pharma Appoints Danielle Campbell as Vice President of

aTyr Pharma Announces Promotion of Leslie Nangle, Ph D , to Vice President of Research

Press release content from Globe Newswire. The AP news staff was not involved in its creation. aTyr Pharma Announces Promotion of Leslie Nangle, Ph.D., to Vice President of Research aTyr Pharma, Inc.May 11, 2021 GMT SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the promotion of Leslie Nangle, Ph.D., to Vice President, Research. Dr. Nangle will serve as a member of the company’s executive leadership team, managing research and scientific operations. Dr. Nangle has served in scientific research roles at aTyr since joining the company in 2007, including most recently as Senior Director and Head of Research.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.